Tier A · Established human benefit
Semaglutide
One of the strongest human evidence bases in modern peptide medicine.
Why researchers care
Potential human relevance
- Substantial, sustained weight reduction in obesity trials
- Improved glycemic control in type 2 diabetes
- Reduced major cardiovascular events in adults with established cardiovascular disease and overweight/obesity
- FDA-approved use for MASH with fibrosis was added in 2025
What the human evidence says
Evidence, not extrapolation
Semaglutide has large randomized human trial programs across diabetes, obesity and cardiovascular disease. Its evidence base is far beyond the typical “research peptide” category.
How to think about it
The Yooper Peptides take
Semaglutide is a useful benchmark for the entire peptide field: a peptide-based therapy can move from biology to rigorous trials to multiple approved indications.
Primary / authoritative reading